Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Assets (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Non-Current Assets data on record, last reported at $15.0 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 88.59% year-over-year to $15.0 million; the TTM value through Sep 2025 reached $48.3 million, up 48.93%, while the annual FY2024 figure was $8.1 million, 2.26% down from the prior year.
  • Non-Current Assets reached $15.0 million in Q3 2025 per ABEO's latest filing, up from $14.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $52.8 million in Q1 2021 and bottomed at $7.9 million in Q3 2024.
  • Average Non-Current Assets over 5 years is $18.1 million, with a median of $11.2 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: crashed 74.05% in 2022, then soared 88.59% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $23.3 million in 2021, then crashed by 52.28% to $11.1 million in 2022, then fell by 25.64% to $8.3 million in 2023, then decreased by 2.26% to $8.1 million in 2024, then skyrocketed by 85.26% to $15.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $15.0 million in Q3 2025, $14.0 million in Q2 2025, and $11.2 million in Q1 2025.